AtriCure (NASDAQ:ATRC) Shares Bought Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on August 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

AtriCure Trading Up 3.0%

Shares of NASDAQ:ATRC traded up $1.58 during mid-day trading on Friday, hitting $54.54. The stock had a trading volume of 1,098,844 shares, compared to its average volume of 835,279. The company’s 50 day moving average is $42.41 and its 200-day moving average is $33.55. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $55.72. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market cap of $2.77 billion, a PE ratio of 259.73 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts predict that AtriCure, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ATRC. Needham & Company LLC upped their price target on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. BTIG Research lifted their target price on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. UBS Group dropped their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Piper Sandler raised their price target on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Hedge Funds Weigh In On AtriCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its stake in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Scotia Capital Inc. boosted its holdings in AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after purchasing an additional 457 shares in the last quarter. ProShare Advisors LLC increased its position in AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock worth $349,000 after buying an additional 543 shares during the last quarter. Captrust Financial Advisors increased its position in AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after buying an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after buying an additional 683 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

Insider Buying and Selling

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Salvatore Privitera sold 3,657 shares of AtriCure stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the completion of the transaction, the insider directly owned 147,264 shares in the company, valued at approximately $8,099,520. This represents a 2.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 65,036 shares of company stock valued at $2,758,687. 4.00% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.